The effects of cyclooxygenase-2 expression in prostate cancer cells: Modulation of response to cytotoxic agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 3, 2008, Pages 1181-1187

  Mehar, Ayaz ^a,b   Macanas Pirard, Patricia ^a   Mizokami, Atsushi ^a,b   Takahashi, Yutaka ^c   Kass, Georges E N ^a   Coley, Helen M ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b KANAZAWA UNIVERSITY   (Japan)

^c OKAYAMA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; CYTOKINE; DESMIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE P1; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN NAG 1; SARCOLYSIN; SULINDAC; SURVIVIN; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYTOTOXINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 40849126882     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.131383     Document Type: Article

References (39)

1. Beurel E and Jope RS (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signalling pathways. Prog Neurobiol 79:173-189.
2. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, and Srivastava RK (2001) Constitutively active AKT is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20:6073-6083.
3. Crocitto LE, Korns D, Kretzner L, Shevchuk T, Blair SL, Wilson TG, Ramin SA, Kawachi MH, and Smith SS (2004) Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 64:821-825.
4. Davies G, Martin LA, Sacks N, and Dowsett M (2002) Cyclooxygenase-2 (COX-2) aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13:669-678.
5. Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ, et al. (2007) A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 25:123-129.
6. Giovannucci E and Willett WC (1994) Dietary factors and risk of colon cancer. Ann Med 26:443-452.
7. Gupta S, Srivastava M, Ahmad N, Bostwick DG, and Mukhtar H (2000) Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42:73-78.
8. Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, and Sakurai K (2003) Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor in human head and neck carcinoma cell lines. Int J Oncol 23:665-672.
9. Javle MM, Cao S, Durrani FA, Pendvala L, Lawrence DD, Smith PF, Creaven PJ, Noel DC, Iver RV, and Rustum YM (2007) Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan and 5-fluorouracil. Clin Cancer Res 13:965-971.
10. Jiang BH, Aoki M, Zheng JZ, Li J, and Vogt PK (1999) Myogenic signalling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc Natl Acad Sci U S A 96:2077-2081.
11. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, and Yoshimoto T (1999) Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1438:120-130.
12. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, et al. (1999) Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29:688-696.
13. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, et al. (2003) Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9:4919-4925.
14. Krysan K, Dalwadi H, Sharma S, Pold M, and Dubinett S (2004a) Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64:6359-6362.
15. Krysan K, Merchant Fh, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Pold M, Seligson D, Chia D, et al. (2004b) COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18:206-208.
16. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone MM, and Stock RG (2005) C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 95:961-962.
17. Lin J, Hsiao P-W, Chiu TH, and Chao J-I (2005) Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 70:658-667.
18. Liu XH, Yao S, Kirschenbaum A, and Levine AC (1998) NS398, a selective cyclooxygenase-2 inhibitor induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58:4245-4249.
19. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
20. Nelson WG, DeWeese TL, and deMarzo AM (2002) The diet, prostate inflammation and the development of prostate cancer. Cancer Metastasis Rev 21:3-16.
21. Nguyen KH (2004) NSAID use confers a survival advantage for prostate cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2182:S445-S446.
22. Okazaki R, Moon Y, Norimura T, and Eling T (2006) Ionizing Radiation enhances the expression of the nonsteroidal anti-inflammatory drug activated gene (NAG1) by increasing the expression of p53 in human colon cancer cells. Radiation Res 165:125-130.
23. Oshima M, Dinchuk JE, Kargman SL, Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, et al. (1996) Suppression of intestinal polyposis in Apcδ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809.
24. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC, and Sessa WC (2000) Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275:9102-9105.
25. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, and Dannenberg AJ (2005) Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2 independent mechanism. Clin Cancer Res 11:1999-2007.
26. Schreinemachers DM and Everson RB (1994) Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 5:138-146.
27. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA, and Chou TC (1999) Synergistic effects of new chemotherapeutic agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59:6178-6184.
28. Soslow R, Dannenburg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, and Koki AT (2000) COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 89:2637-2645.
29. Sun XY, Donald SP, and Phang JM (2001) Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22:1775-1780.
30. Tanji N, Kikugawa T, and Yokoyama M (2000) Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression. Antiicancer Res 20:2313-2319.
31. Townsend DM and Tew KD (2003) The role of glutathione-S-transferase in anticancer drug resistance. Oncogene 22:7369-7375.
32. Tsujii M and DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501.
33. Tucker ON, Dannenburg AJ, Yang EK, Zhang F, Teng L, Daly JM, Sosolow RA, Masferrer JL, Woerner BM, Koki AT, et al. (1999) Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59:987-990.
34. van der Horst A and Burgering BM (2007) Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 8:440-450.
35. Wang W, Bergh A, and Damber JE (2005) Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate. Clin Cancer Res 11:3250-3256.
36. Wong YC and Tam NNC (2002) Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. Dedifferentiation 70:633-645.
37. Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, and Nakano T (2006) COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 18:41-47.
38. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, and Wada S (2000) Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89:589-596.
39. Zha S, Gage WR, Sauvagoet J, Sria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, de Marzo AM, and Isaacs WB (2001) Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate but not in prostate carcinoma. Cancer Res 61:8617-8623.